Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide
Autore:
Polyzos, A; Tsavaris, N; Kosmas, C; Petrikos, G; Giannikos, L; Kalahanis, N; Papadopoulos, O; Christodoulou, K; Giannakopoulos, K; Veslemes, M; Katsilambros, N;
Indirizzi:
Univ Athens, Laikon Hosp, Sch Med, Dept Prop Med 1, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 t Prop Med 1, GR-11527 Athens, Greece
Titolo Testata:
JOURNAL OF CHEMOTHERAPY
fascicolo: 2, volume: 11, anno: 1999,
pagine: 144 - 149
SICI:
1120-009X(199904)11:2<144:SCWCIP>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-II TRIAL; SALVAGE THERAPY; RANDOMIZED TRIAL; CARCINOMA; PLATINUM; MESNA; DOXORUBICIN; VINBLASTINE; DISEASE;
Keywords:
ovarian cancer; second-line chemotherapy; ifosfamide; cisplatin; carboplatin; cyclophosphamide;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Polyzos, A Univ Athens, Laikon Hosp, Sch Med, Dept Prop Med 1, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 1, GR-11527 Athens, Greece
Citazione:
A. Polyzos et al., "Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide", J CHEMOTHER, 11(2), 1999, pp. 144-149

Abstract

In an effort to use antineoplastic drug combinations which are active in platinum resistant ovarian cancer or which can induce a second response after a platinum first-line treatment, we conducted a study on 30 ovarian cancer patients previously treated with carboplatin plus cyclophosphamide who were given ifosfamide 5 g/m(2) i.v. divided over days 1 to 3 plus mesma combined with cisplatin 100 mg/m(2) i.v, divided over days 1. to 3 every 4 weeksas second-line treatment. Eight patients had never entered remission with first-line chemotherapy while 22 patients had tumor recurrence within 6 to 18 months after the end of chemotherapy and their tumors were considered potentially platinum sensitive. Responding patients received 6 courses while palliative treatment for nonresponders was provided, Of the 22 patients with tumor recurrence, 8 patients responded with one partial response (PR) and7 complete clinical responses (CCR), Two out of the 8 patients with platinum resistant disease demonstrated short lasting PR. Seven patients with CCRunderwent second-look operation and in two a pathological CR was documented. Median time to progression was 6 mo (4-12), The median overall survival was 12 mo (4-20), Myelotoxicity despite G-CSF administration was significant with grade 4 leukopenia in 40% and grade 3 thrombocytopenia in 20% of patients. Central nervous system (CNS) toxicity was significant with 30% somnolence, 20% disorientation and an episode of grand-mal epilepsy ascribed to ifosfamide, With a 33% response rate the combination is as effective as newagents employed in relapsed ovarian cancer. Platinum-refractory disease may respond to a lesser degree. The most important determinant of response was the progression-free interval from first-line chemotherapy. Whether patients recurring after carboplatin plus cyclophosphamide have a greater chanceto respond to cisplatin plus ifosfamide or vice-versa cannot be supported by the current data and therefore randomized studies should be performed tothis end.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 08:22:35